Low-dose IL-2 for patients with systemic lupus erythematosus – Authors' reply

Research Areas and Centers

This output contributes to the following UN Sustainable Development Goals (SDGs)

@article{d2cc00ffd3b043749126ae1dc5369350,

title = "Low-dose IL-2 for patients with systemic lupus erythematosus – Authors' reply",

author = "Humrich, {Jens Y.} and Gabriela Riemekasten",

year = "2019",

month = dec,

doi = "10.1016/S2665-9913(19)30106-7",

language = "English",

volume = "1",

pages = "e203--e204",

journal = "The Lancet Rheumatology",

issn = "2665-9913",

number = "4",

}

TY - JOUR

T1 - Low-dose IL-2 for patients with systemic lupus erythematosus – Authors' reply

AU - Humrich, Jens Y.

AU - Riemekasten, Gabriela

PY - 2019/12

Y1 - 2019/12

UR - http://www.scopus.com/inward/record.url?scp=85078222649&partnerID=8YFLogxK

U2 - 10.1016/S2665-9913(19)30106-7

DO - 10.1016/S2665-9913(19)30106-7

M3 - Letters

AN - SCOPUS:85078222649

SN - 2665-9913

VL - 1

SP - e203-e204

JO - The Lancet Rheumatology

JF - The Lancet Rheumatology

IS - 4

ER -